26 results on '"Lynch, Thomas J."'
Search Results
2. Abstract 142: Mutation and immune profiles in early-stage lung squamous cell carcinoma
3. Abstract 89: Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma
4. Two Sides of the Same Coin: EGFR Exon 19 Deletions and Insertions in Lung Cancer: Figure 1.
5. Integration of Molecular Profiling into the Lung Cancer Clinic
6. Vascular Endothelial Growth Factor Polymorphisms and Esophageal Cancer Prognosis
7. p53 Arg72Pro and MDM2 T309G Polymorphisms, Histology, and Esophageal Cancer Prognosis
8. A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors
9. Phase I and Pharmacokinetic Study of Gimatecan Given Orally Once a Week for 3 of 4 Weeks in Patients with Advanced Solid Tumors
10. Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non–Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment
11. Vascular Endothelial Growth Factor Genotypes, Haplotypes, Gender, and the Risk of Non–Small Cell Lung Cancer
12. A Rapid Outcomes Ascertainment System Improves the Quality of Prognostic and Pharmacogenetic Outcomes from Observational Studies
13. Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference
14. Second Hand Smoke Exposure and Survival in Early-Stage Non–Small-Cell Lung Cancer Patients
15. Matrix Metalloproteinase Polymorphisms and Survival in Stage I Non–Small Cell Lung Cancer
16. Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents
17. Epidermal Growth Factor Receptor Mutation Testing in the Care of Lung Cancer Patients
18. Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer: Predicting Clinical Response to Kinase Inhibitors
19. Early Stage Lung Cancer—New Approaches to Evaluation and Treatment: Conference Summary Statement
20. Phase I Trial of the Matrix Metalloproteinase Inhibitor Marimastat Combined with Carboplatin and Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer
21. Matrix Metalloproteinase-1 Promoter Polymorphism and Lung Cancer Risk
22. Polymorphisms in ERCC1 and Grade 3 or 4 Toxicity in Non–Small Cell Lung Cancer Patients
23. Gene-Smoking Interaction Associations for the ERCC1 Polymorphisms in the Risk of Lung Cancer
24. Excision Repair Cross-Complementation Group 1 Polymorphism Predicts Overall Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy
25. Novel Agents in the Treatment of Lung Cancer
26. Phase I Clinical Trial of the Farnesyltransferase Inhibitor BMS-214662 Given as a 1-Hour Intravenous Infusion in Patients with Advanced Solid Tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.